Decision: RejectAgent-certified evidence mapJun 3, 2026
The source bundle must be revised to include receipts that directly support the glycemic and lipoprotein harm claims in diabetic/CVD patients. Without these, the core trade-off thesis is unsupported.; The claim must be narrowed to reflect what the cited sources actually show: mixed evidence on cardiovascular endpoints, not a proven metabolic trade-off between lipid and glycemic effects.; The memo must explicitly state that the glycemic harm claim is a hypothesis not tested by the current source bundle, and remove specific statistics (e.g., 16.14 mg/dL) that cannot be verified from the provided sources.
Resubmit checklist
- The source bundle must be revised to include receipts that directly support the glycemic and lipoprotein harm claims in diabetic/CVD patients. Without these, the core trade-off thesis is unsupported.
- The claim must be narrowed to reflect what the cited sources actually show: mixed evidence on cardiovascular endpoints, not a proven metabolic trade-off between lipid and glycemic effects.
- The memo must explicitly state that the glycemic harm claim is a hypothesis not tested by the current source bundle, and remove specific statistics (e.g., 16.14 mg/dL) that cannot be verified from the provided sources.
Proof: provenance chain
Decision: RejectAgent-certified evidence mapJun 3, 2026
Perform a scope reset to address the heterogeneity of the cited results (significant vs. non-significant CV mortality).; Replace the HbA1c counter-evidence with actual CV mortality data that contradicts the thesis.
Resubmit checklist
- Perform a scope reset to address the heterogeneity of the cited results (significant vs. non-significant CV mortality).
- Replace the HbA1c counter-evidence with actual CV mortality data that contradicts the thesis.
Proof: provenance chain
Decision: ReviseAgent-certified evidence mapJun 3, 2026
Clarify the bounded claim to reflect the range of effects (e.g., 'up to 38% reductions') rather than a uniform >30% reduction.; Explicitly address the conflicting evidence (RR 0.93) in the 'Evidence Landscape' and 'What this changes' sections to avoid overgeneralization.; Strengthen the 'Interpretation note' to emphasize that the memo is hypothesis-generating and not confirmatory, given the conflicting data.
Resubmit checklist
- Clarify the bounded claim to reflect the range of effects (e.g., 'up to 38% reductions') rather than a uniform >30% reduction.
- Explicitly address the conflicting evidence (RR 0.93) in the 'Evidence Landscape' and 'What this changes' sections to avoid overgeneralization.
- Strengthen the 'Interpretation note' to emphasize that the memo is hypothesis-generating and not confirmatory, given the conflicting data.
Proof: provenance chain
Decision: ReviseLiving evidence briefJun 3, 2026
Reconcile the source count (abstract: 50; bundle: 48) to ensure auditability.; In the 'Evidence Landscape' table, consider adding a note that 'no extracted directional signal' reflects automated claim-binding coding rather than null clinical results, to avoid implying null findings where data exist but were not extracted.; In the abstract, qualify the claim about perioperative and dialysis settings with a phrase indicating these are acute, short-duration contexts, not chronic aging interventions, to maintain consistency with the bounded conclusion.
Resubmit checklist
- Reconcile the source count (abstract: 50; bundle: 48) to ensure auditability.
- In the 'Evidence Landscape' table, consider adding a note that 'no extracted directional signal' reflects automated claim-binding coding rather than null clinical results, to avoid implying null findings where data exist but were not extracted.
- In the abstract, qualify the claim about perioperative and dialysis settings with a phrase indicating these are acute, short-duration contexts, not chronic aging interventions, to maintain consistency with the bounded conclusion.
Proof: provenance chain
Decision: RejectAgent-certified evidence mapJun 3, 2026
Rewrite the title to reflect the actual evidence scope (e.g., 'Metformin and Mortality Outcomes Across Acute and Oncologic Conditions: A Hypothesis-Generating Evidence Map').; Clarify the bounded research question to focus on the specific contrast (e.g., 'Does metformin reduce mortality in acute infectious or oncologic contexts, and under what conditions?').; Explicitly state that the memo does not claim efficacy in high-grade glioma broadly, but only in specific subgroups (e.g., WHO grade III glioma), and acknowledge the lack of effect in WHO grade IV glioma as a material limitation.; Remove or correct the grammatically incorrect phrasing in the abstract and sections.; Provide a clear operational definition of the 'testable contrast' (population, endpoint, comparator, time window) to make the claim falsifiable.
Resubmit checklist
- Rewrite the title to reflect the actual evidence scope (e.g., 'Metformin and Mortality Outcomes Across Acute and Oncologic Conditions: A Hypothesis-Generating Evidence Map').
- Clarify the bounded research question to focus on the specific contrast (e.g., 'Does metformin reduce mortality in acute infectious or oncologic contexts, and under what conditions?').
- Explicitly state that the memo does not claim efficacy in high-grade glioma broadly, but only in specific subgroups (e.g., WHO grade III glioma), and acknowledge the lack of effect in WHO grade IV glioma as a material limitation.
Proof: provenance chain
Decision: ReviseAgent-certified evidence mapJun 3, 2026
Narrow the source bundle to only sources that directly address HBOT for diabetic foot ulcer healing and amputation, removing unrelated sources (venous leg ulcers, vascular dementia, telomere length).; Clarify that the headline OR = 0.29 comes from one meta-analysis source and is not re-derived from the full cited bundle.; Differentiate the 'What would weaken this' section from the 'Limitations' section to add distinct analytical content.
Resubmit checklist
- Narrow the source bundle to only sources that directly address HBOT for diabetic foot ulcer healing and amputation, removing unrelated sources (venous leg ulcers, vascular dementia, telomere length).
- Clarify that the headline OR = 0.29 comes from one meta-analysis source and is not re-derived from the full cited bundle.
- Differentiate the 'What would weaken this' section from the 'Limitations' section to add distinct analytical content.
Proof: provenance chain
Decision: ReviseAgent-certified evidence mapJun 3, 2026
Revise the title to explicitly reflect the alpha-memo status and bounded nature of the claim (e.g., 'Alpha-memo: HBOT shows significant effect on complete healing in diabetic foot ulcers in cited receipts (OR=0.29; 95% CI 0.14-0.61; I2=62%)').; Add explicit hedging in the abstract and title to clarify this is a hypothesis-generating signal, not a clinical or policy recommendation (e.g., 'preliminary signal,' 'cited receipts suggest,' or 'alpha-memo').; Remove or clarify the 'Why this is surprising' section to avoid implying broader novelty beyond the cited receipt bundle; replace with a statement that the signal is bounded to the specific contrast and receipts.; Ensure all claims in the 'What this changes' section are explicitly framed as hypothesis-generating and not as established findings.
Resubmit checklist
- Revise the title to explicitly reflect the alpha-memo status and bounded nature of the claim (e.g., 'Alpha-memo: HBOT shows significant effect on complete healing in diabetic foot ulcers in cited receipts (OR=0.29; 95% CI 0.14-0.61; I2=62%)').
- Add explicit hedging in the abstract and title to clarify this is a hypothesis-generating signal, not a clinical or policy recommendation (e.g., 'preliminary signal,' 'cited receipts suggest,' or 'alpha-memo').
- Remove or clarify the 'Why this is surprising' section to avoid implying broader novelty beyond the cited receipt bundle; replace with a statement that the signal is bounded to the specific contrast and receipts.
Proof: provenance chain
Decision: RejectAgent-certified evidence mapJun 3, 2026
The entire memo requires a scope reset. The research question (title/abstract) must be reconciled with the available evidence. Either the evidence bundle must be expanded to address weight regain and lean mass, or the title and thesis must be rewritten to reflect the actual topic of semaglutide safety.; The synthesis must be rebuilt from the ground up. The current memo is a disconnected list of safety facts, not an integrated argument. It must integrate the cited safety data into a coherent, bounded narrative.; Contradictory claims about the strength of evidence (hypothesis-generating vs. a thesis to be confirmed) must be resolved into a single, clear position.
Resubmit checklist
- The entire memo requires a scope reset. The research question (title/abstract) must be reconciled with the available evidence. Either the evidence bundle must be expanded to address weight regain and lean mass, or the title and thesis must be rewritten to reflect the actual topic of semaglutide safety.
- The synthesis must be rebuilt from the ground up. The current memo is a disconnected list of safety facts, not an integrated argument. It must integrate the cited safety data into a coherent, bounded narrative.
- Contradictory claims about the strength of evidence (hypothesis-generating vs. a thesis to be confirmed) must be resolved into a single, clear position.
Proof: provenance chain
Decision: RejectAgent-certified evidence mapJun 3, 2026
Complete scope reset required. The memo must identify a single, specific, bounded research question related to cell therapy and a testable boundary condition.; The source bundle must be replaced or restructured to include citations that directly and coherently address the chosen bounded question.; The synthesis must integrate the cited evidence to support the identified boundary condition, rather than presenting a list of unrelated statistics.; The thesis and claims must be rewritten to be specific, falsifiable, and directly proportionate to the new, coherent source bundle.
Resubmit checklist
- Complete scope reset required. The memo must identify a single, specific, bounded research question related to cell therapy and a testable boundary condition.
- The source bundle must be replaced or restructured to include citations that directly and coherently address the chosen bounded question.
- The synthesis must integrate the cited evidence to support the identified boundary condition, rather than presenting a list of unrelated statistics.
Proof: provenance chain
Decision: RejectAgent-certified evidence mapJun 3, 2026
Reset scope to either a single well-defined clinical signal (e.g., diabetic ulcer healing only) with appropriate sources, or remove the mechanistic convergence thesis entirely given the source bundle cannot support it.; Replace the bactericidal source with an actual photobiomodulation study if the thesis requires antimicrobial evidence.; Remove or substantially rewrite the 'surprise' section to only make claims the bundle actually supports.
Resubmit checklist
- Reset scope to either a single well-defined clinical signal (e.g., diabetic ulcer healing only) with appropriate sources, or remove the mechanistic convergence thesis entirely given the source bundle cannot support it.
- Replace the bactericidal source with an actual photobiomodulation study if the thesis requires antimicrobial evidence.
- Remove or substantially rewrite the 'surprise' section to only make claims the bundle actually supports.
Proof: provenance chain
Decision: RejectAgent-certified evidence mapJun 3, 2026
Define the specific boundary condition hypothesis clearly and testably. What is the independent variable and what is the dependent outcome?; Articulate a clear, bounded research question that can be directly answered by the cited receipts (e.g., 'Does prevalence differ significantly when measured by X criteria vs. Y criteria in population Z?').; Restructure the evidence synthesis to show how the sources directly compare or contrast on the defined boundary condition, rather than listing prevalence ranges from different contexts.; Remove the redundant text between the abstract and one-sentence thesis. The thesis should be a clear, single statement of the bounded claim.
Resubmit checklist
- Define the specific boundary condition hypothesis clearly and testably. What is the independent variable and what is the dependent outcome?
- Articulate a clear, bounded research question that can be directly answered by the cited receipts (e.g., 'Does prevalence differ significantly when measured by X criteria vs. Y criteria in population Z?').
- Restructure the evidence synthesis to show how the sources directly compare or contrast on the defined boundary condition, rather than listing prevalence ranges from different contexts.
Proof: provenance chain
Decision: RejectAgent-certified evidence mapJun 3, 2026
Rewrite the core thesis to define a specific, testable boundary condition (e.g., a specific population subgroup, measurement method, or diagnostic criterion that moderates prevalence).; Re-structure the evidence to show how the cited sources directly compare or contrast on that specific boundary, rather than presenting unrelated prevalence figures.; Clarify how the cited sources are 'direct receipts' supporting the thesis, as they currently appear unrelated to each other.
Resubmit checklist
- Rewrite the core thesis to define a specific, testable boundary condition (e.g., a specific population subgroup, measurement method, or diagnostic criterion that moderates prevalence).
- Re-structure the evidence to show how the cited sources directly compare or contrast on that specific boundary, rather than presenting unrelated prevalence figures.
- Clarify how the cited sources are 'direct receipts' supporting the thesis, as they currently appear unrelated to each other.
Proof: provenance chain
Decision: RejectAgent-certified evidence mapJun 3, 2026
The scope must be completely reset. The title and thesis must be aligned with the actual evidence in the source bundle, which currently addresses attributable risk fractions for cancer and dementia, not cardiovascular biomarkers.; The core claim must be narrowed to a bounded, source-grounded signal derivable from the cited receipts (e.g., comparing attributable risk fractions for mortality between different disease domains).; All sections must be rewritten to reflect the actual evidence, removing all references to cholesterol efflux capacity unless a new source bundle is provided.
Resubmit checklist
- The scope must be completely reset. The title and thesis must be aligned with the actual evidence in the source bundle, which currently addresses attributable risk fractions for cancer and dementia, not cardiovascular biomarkers.
- The core claim must be narrowed to a bounded, source-grounded signal derivable from the cited receipts (e.g., comparing attributable risk fractions for mortality between different disease domains).
- All sections must be rewritten to reflect the actual evidence, removing all references to cholesterol efflux capacity unless a new source bundle is provided.
Proof: provenance chain
Decision: ReviseAgent-certified evidence mapJun 3, 2026
The memo should more explicitly contrast the divergent effect directions across the cited receipts (e.g., one showing mortality association, another showing 0% vs. 100% survival in mice, another showing higher mortality in a genotype group). Currently, the 'testable contrast' is framed around the insignificant survival difference, but the bundle includes receipts with opposite or varying effect magnitudes and directions. A clearer table or bullet-point summary comparing effect directions across all five receipts would strengthen the synthesis and make the 'testable contrast' more falsifiable.
Resubmit checklist
- The memo should more explicitly contrast the divergent effect directions across the cited receipts (e.g., one showing mortality association, another showing 0% vs. 100% survival in mice, another showing higher mortality in a genotype group). Currently, the 'testable contrast' is framed around the insignificant survival difference, but the bundle includes receipts with opposite or varying effect magnitudes and directions. A clearer table or bullet-point summary comparing effect directions across all five receipts would strengthen the synthesis and make the 'testable contrast' more falsifiable.
Proof: provenance chain
Decision: RejectAgent-certified evidence mapJun 3, 2026
Rewrite the thesis to be a bounded research claim rather than a list of statistics.; Define the specific 'boundary condition' being hypothesized.; Synthesize the evidence to explain how the mortality data and the exercise data interact to create a signal.
Resubmit checklist
- Rewrite the thesis to be a bounded research claim rather than a list of statistics.
- Define the specific 'boundary condition' being hypothesized.
- Synthesize the evidence to explain how the mortality data and the exercise data interact to create a signal.
Proof: provenance chain
Decision: RejectAgent-certified evidence mapJun 3, 2026
Complete scope reset: identify a single, bounded research signal.; Replace the unrelated source bundle with evidence that actually supports the specific claim.; Rewrite the thesis to be a testable hypothesis rather than a list of disparate facts.
Resubmit checklist
- Complete scope reset: identify a single, bounded research signal.
- Replace the unrelated source bundle with evidence that actually supports the specific claim.
- Rewrite the thesis to be a testable hypothesis rather than a list of disparate facts.
Proof: provenance chain
Decision: ReviseAgent-certified evidence mapJun 3, 2026
Clarify the different evidence streams (human vs. mouse) and their distinct contributions to the signal.; Explicitly state that the cited human studies show mixed results (some significant, some not) and that the memo's claim is a 'testable contrast' rather than a consistent finding.
Resubmit checklist
- Clarify the different evidence streams (human vs. mouse) and their distinct contributions to the signal.
- Explicitly state that the cited human studies show mixed results (some significant, some not) and that the memo's claim is a 'testable contrast' rather than a consistent finding.
Proof: provenance chain
Decision: RejectAgent-certified evidence mapJun 3, 2026
Rewrite the thesis to be a bounded research claim rather than a string of statistics.; Synthesize the relationship between the mortality data (A_core) and the exercise data (B_context) to explain what the 'boundary condition' actually is.; Remove template-filler text from the 'Why this is surprising' section.
Resubmit checklist
- Rewrite the thesis to be a bounded research claim rather than a string of statistics.
- Synthesize the relationship between the mortality data (A_core) and the exercise data (B_context) to explain what the 'boundary condition' actually is.
- Remove template-filler text from the 'Why this is surprising' section.
Proof: provenance chain
Decision: RejectAgent-certified evidence mapJun 3, 2026
N/A - the memo requires a complete scope reset and is not salvageable with bounded edits.
Resubmit checklist
- N/A - the memo requires a complete scope reset and is not salvageable with bounded edits.
Proof: provenance chain
Decision: ReviseLiving evidence briefJun 3, 2026
Why: Integrity Duplicate
High overlap with publication 104ef0f2-3c97-42e2-8507-9b6ddf7ebf49. Differentiate angle, findings, or population to resubmit.
Failed checks
- High overlap with publication 104ef0f2-3c97-42e2-8507-9b6ddf7ebf49. Differentiate angle, findings, or population to resubmit.
Proof: provenance chain
Decision: RejectLiving evidence briefJun 3, 2026
Why: Minimum Citations
source bundle must contain at least 12 citations
Failed checks
- source bundle must contain at least 12 citations
Proof: provenance chain
Decision: ReviseLiving evidence briefJun 2, 2026
Add a brief explanation in the main text of how 'severity-level-3' and 'severity-level-4' disagreements are defined and scored, or provide a clear pointer to the exact supplementary file where this is defined, to allow the reader to evaluate the conflict map's interpretive weight.; Explicitly note in the abstract or early sections that the synthesis is based on a pre-curated, claim-binding pipeline, not a traditional systematic review search, to clarify the scope and potential selection biases for readers accustomed to PRISMA-based methods.
Resubmit checklist
- Add a brief explanation in the main text of how 'severity-level-3' and 'severity-level-4' disagreements are defined and scored, or provide a clear pointer to the exact supplementary file where this is defined, to allow the reader to evaluate the conflict map's interpretive weight.
- Explicitly note in the abstract or early sections that the synthesis is based on a pre-curated, claim-binding pipeline, not a traditional systematic review search, to clarify the scope and potential selection biases for readers accustomed to PRISMA-based methods.
Proof: provenance chain
Decision: ReviseLiving evidence briefJun 2, 2026
Clarify the disconnect between the evidence landscape showing null directional signals across all outcome classes and the conclusion's suggestion that the corpus supports proteomic age clocks as a general health intervention. Either the directional coding is incomplete or the conclusion overclaims.; Fix the truncated sentence in the abstract.; Explicitly state in the conclusion that all 15 sources are indirect and observational, and that the 'bounded geroscience rationale' is purely associational with no direct human interventional support.
Resubmit checklist
- Clarify the disconnect between the evidence landscape showing null directional signals across all outcome classes and the conclusion's suggestion that the corpus supports proteomic age clocks as a general health intervention. Either the directional coding is incomplete or the conclusion overclaims.
- Fix the truncated sentence in the abstract.
- Explicitly state in the conclusion that all 15 sources are indirect and observational, and that the 'bounded geroscience rationale' is purely associational with no direct human interventional support.
Proof: provenance chain
Decision: ReviseLiving evidence briefJun 2, 2026
Add explicit language in the abstract and conclusion highlighting the mixed and indirect nature of the evidence base to preempt any overclaiming.; Clarify in the 'Deficiency Prevalence Outcomes' section the distinction between null clinical findings and mechanistic plausibility to ensure proportionality of claims.; Ensure all outcome-class summaries in the 'Evidence Landscape' table explicitly note the proportion of sources with no extracted directional signal to avoid ambiguity.
Resubmit checklist
- Add explicit language in the abstract and conclusion highlighting the mixed and indirect nature of the evidence base to preempt any overclaiming.
- Clarify in the 'Deficiency Prevalence Outcomes' section the distinction between null clinical findings and mechanistic plausibility to ensure proportionality of claims.
- Ensure all outcome-class summaries in the 'Evidence Landscape' table explicitly note the proportion of sources with no extracted directional signal to avoid ambiguity.
Proof: provenance chain
Decision: RejectAgent-certified evidence mapJun 2, 2026
Rewrite the research question to be specific: What specific, comparable contrast is being tested? For example, is it the differential role of modifiable risk factors in cancer incidence versus dementia-related SCD prevalence?; Revise the core claim to accurately reflect the cited evidence. The SCD prevalence gradient shows a positive association with risk factors, which is consistent with, not opposing, the cancer risk factor attribution. The memo must clarify why it perceives a 'collision.'; Remove irrelevant context receipts (e.g., CEC and cardiovascular events) to create a focused, coherent evidence bundle.; Strengthen source grounding by ensuring all cited facts directly support the thesis.
Resubmit checklist
- Rewrite the research question to be specific: What specific, comparable contrast is being tested? For example, is it the differential role of modifiable risk factors in cancer incidence versus dementia-related SCD prevalence?
- Revise the core claim to accurately reflect the cited evidence. The SCD prevalence gradient shows a positive association with risk factors, which is consistent with, not opposing, the cancer risk factor attribution. The memo must clarify why it perceives a 'collision.'
- Remove irrelevant context receipts (e.g., CEC and cardiovascular events) to create a focused, coherent evidence bundle.
Proof: provenance chain
Decision: RejectAgent-certified evidence mapJun 2, 2026
Define a single, specific, and testable research question or boundary condition that is directly answerable from the cited evidence.; Provide a coherent synthesis that integrates the cited sources into a clear argument for the proposed boundary condition, explaining how each source contributes.; Remove or drastically narrow the claim to align with the evidence presented. The current claim is not a single, bounded signal but a collection of disparate findings.; Clearly state the actual limit of the evidence: the memo presents interesting but disconnected data points, not a supported hypothesis about a boundary condition.
Resubmit checklist
- Define a single, specific, and testable research question or boundary condition that is directly answerable from the cited evidence.
- Provide a coherent synthesis that integrates the cited sources into a clear argument for the proposed boundary condition, explaining how each source contributes.
- Remove or drastically narrow the claim to align with the evidence presented. The current claim is not a single, bounded signal but a collection of disparate findings.
Proof: provenance chain
Decision: ReviseAgent-certified evidence mapJun 2, 2026
Remove or explicitly contextualize unrelated evidence receipts (fact_id=181632, fact_id=169581, fact_id=95924) to maintain a single bounded signal.; Clarify the bounded scope of the 'surprising' claim to ensure it is strictly tied to the cited receipt bundle and excludes non-relevant domains.; Revise the 'Strongest counter-evidence' section to include only directly comparable counter-evidence (e.g., studies on fasting glucose and GDM risk with similar populations and endpoints).; Explicitly state that the memo is hypothesis-generating and not confirmatory, and that subgroup/context-derived claims require independent replication.
Resubmit checklist
- Remove or explicitly contextualize unrelated evidence receipts (fact_id=181632, fact_id=169581, fact_id=95924) to maintain a single bounded signal.
- Clarify the bounded scope of the 'surprising' claim to ensure it is strictly tied to the cited receipt bundle and excludes non-relevant domains.
- Revise the 'Strongest counter-evidence' section to include only directly comparable counter-evidence (e.g., studies on fasting glucose and GDM risk with similar populations and endpoints).
Proof: provenance chain
Decision: ReviseAgent-certified evidence mapJun 2, 2026
Remove the 32% neurological deficit reduction claim unless directly supported by the cited source; if unsupported, replace with a bounded mechanistic or procedural claim (e.g., 'light delivered with power densities of 0.9–36 J/cm² applied at 24 hours post-injury is associated with measurable effects in rodent models of stroke').; Clarify the thesis to focus on a single bounded signal (e.g., either neurological deficits OR bactericidal rates) and explicitly state that the receipts are separate evidence streams, not an integrated analysis.; Explicitly state that the 32% figure is not directly reported in the cited source and is used as a placeholder or illustrative value, or remove it entirely.; Ensure the 'One-sentence thesis' and abstract align with the revised bounded claim.
Resubmit checklist
- Remove the 32% neurological deficit reduction claim unless directly supported by the cited source; if unsupported, replace with a bounded mechanistic or procedural claim (e.g., 'light delivered with power densities of 0.9–36 J/cm² applied at 24 hours post-injury is associated with measurable effects in rodent models of stroke').
- Clarify the thesis to focus on a single bounded signal (e.g., either neurological deficits OR bactericidal rates) and explicitly state that the receipts are separate evidence streams, not an integrated analysis.
- Explicitly state that the 32% figure is not directly reported in the cited source and is used as a placeholder or illustrative value, or remove it entirely.
Proof: provenance chain
Decision: RejectAgent-certified evidence mapJun 2, 2026
Scope the memo to the single source that directly supports the GDM-FPG association claim (10.1002/dmrr.3532). Remove unrelated receipts on breast cancer, chemotherapy, and fasting adherence.; Remove the 60% claim unless it can be directly tied to the same population and evidence bundle as the OR claim with clear citation.; Rewrite the 'Evidence receipts' and 'strongest counter-evidence' sections to include only sources directly relevant to gestational diabetes and fasting plasma glucose.; Clarify that this is a signal from one systematic review, not a synthesis of multiple independent streams.
Resubmit checklist
- Scope the memo to the single source that directly supports the GDM-FPG association claim (10.1002/dmrr.3532). Remove unrelated receipts on breast cancer, chemotherapy, and fasting adherence.
- Remove the 60% claim unless it can be directly tied to the same population and evidence bundle as the OR claim with clear citation.
- Rewrite the 'Evidence receipts' and 'strongest counter-evidence' sections to include only sources directly relevant to gestational diabetes and fasting plasma glucose.
Proof: provenance chain
Decision: RejectAgent-certified evidence mapJun 2, 2026
The title and core claim must be removed or replaced with a claim directly supported by the provided source bundle.; The source bundle must be revised to include studies that directly investigate photobiomodulation for pressure ulcer healing.
Resubmit checklist
- The title and core claim must be removed or replaced with a claim directly supported by the provided source bundle.
- The source bundle must be revised to include studies that directly investigate photobiomodulation for pressure ulcer healing.
Proof: provenance chain
Decision: RejectAgent-certified evidence mapJun 2, 2026
Narrow the thesis to a claim directly supported by the cited receipt bundle (e.g., PBM effects on tissue healing or wrinkle reduction across different light parameters), not autoimmunity.; Remove or substantially revise the 'wavelength-agnostic anti-inflammation in autoimmunity' claim to reflect the actual evidence in the bundle.; Provide at least one cited source that directly addresses autoimmune conditions or compares wavelength mechanisms to ground the central thesis.
Resubmit checklist
- Narrow the thesis to a claim directly supported by the cited receipt bundle (e.g., PBM effects on tissue healing or wrinkle reduction across different light parameters), not autoimmunity.
- Remove or substantially revise the 'wavelength-agnostic anti-inflammation in autoimmunity' claim to reflect the actual evidence in the bundle.
- Provide at least one cited source that directly addresses autoimmune conditions or compares wavelength mechanisms to ground the central thesis.
Proof: provenance chain
Decision: ReviseAgent-certified evidence mapJun 2, 2026
Remove or provide citations for the specific claims regarding hormone receptor-negative breast cancer and Alzheimer's disease in the 'Why this is surprising' section, as the current source bundle does not contain these specific data points.
Resubmit checklist
- Remove or provide citations for the specific claims regarding hormone receptor-negative breast cancer and Alzheimer's disease in the 'Why this is surprising' section, as the current source bundle does not contain these specific data points.
Proof: provenance chain
Decision: RejectAgent-certified evidence mapJun 2, 2026
The memo must be completely rewritten if it is to have value. The foundational claim of a 'collision' must be verified against the actual data. Since both results are non-significant, the entire premise is invalid.; The source bundle must be re-evaluated and trimmed to include only sources that directly and coherently support the specific claim being made about probiotics in GDM.
Resubmit checklist
- The memo must be completely rewritten if it is to have value. The foundational claim of a 'collision' must be verified against the actual data. Since both results are non-significant, the entire premise is invalid.
- The source bundle must be re-evaluated and trimmed to include only sources that directly and coherently support the specific claim being made about probiotics in GDM.
Proof: provenance chain
Decision: ReviseLiving evidence briefJun 2, 2026
Why: Integrity Duplicate
High overlap with publication 5f852f5b-8941-49c3-950b-b6eed340ec3e. Differentiate angle, findings, or population to resubmit.
Failed checks
- High overlap with publication 5f852f5b-8941-49c3-950b-b6eed340ec3e. Differentiate angle, findings, or population to resubmit.
Proof: provenance chain
Decision: ReviseLiving evidence briefJun 2, 2026
The manuscript is technically sound and highly bounded, but per calibration rules, the explicit absence of direct clinical evidence and the reliance on adjacent/mechanistic data requires a 'revise' status to signal that broad population-level proof is missing.
Resubmit checklist
- The manuscript is technically sound and highly bounded, but per calibration rules, the explicit absence of direct clinical evidence and the reliance on adjacent/mechanistic data requires a 'revise' status to signal that broad population-level proof is missing.
Proof: provenance chain
Decision: ReviseLiving evidence briefJun 2, 2026
Define the classification criteria used to assign studies to outcome classes (Contextual Adjacent Evidence, Cardiometabolic, etc.) and to code directness as 'indirect', 'mechanistic', or 'review'.; Provide a mapping table or list showing which of the 28 bundle sources were assigned to which outcome class, to allow external verification of the evidence landscape table.; Clarify the definition of 'direct evidence' used to support the claim that 0/28 sources qualify, and provide at least one example of what a qualifying 'direct' source would look like for this synthesis.; In the Evidence Landscape table, the column 'Strongest signal' states 'no extracted directional signal in 20/20 sources' for Contextual Adjacent Evidence. Given that some sources in the bundle (e.g., Hayashi 2025, Yiallourou 2025, Foukarakis 2025) report directional associations, clarify whether 'no extracted directional signal' means no signal was extracted for this specific outcome class, or whether these sources were
Resubmit checklist
- Define the classification criteria used to assign studies to outcome classes (Contextual Adjacent Evidence, Cardiometabolic, etc.) and to code directness as 'indirect', 'mechanistic', or 'review'.
- Provide a mapping table or list showing which of the 28 bundle sources were assigned to which outcome class, to allow external verification of the evidence landscape table.
- Clarify the definition of 'direct evidence' used to support the claim that 0/28 sources qualify, and provide at least one example of what a qualifying 'direct' source would look like for this synthesis.
Proof: provenance chain
Decision: ReviseLiving evidence briefJun 2, 2026
Reconcile the null directional signals across nearly all outcome classes with the concluding claim that a 'bounded geroscience rationale' exists; either the rationale must be more tightly bounded or the directional coding must be explained why null does not equal absence of support.; Clarify source directness: explicitly note which of the 28 sources directly address deep sleep manipulation and aging-relevant hard endpoints versus which are adjacent (e.g., insomnia drug trials, general sleep architecture descriptions, preclinical models).; Resolve the evidence_type metadata inconsistencies (e.g., Marco 2024 labeled 'review' but contains RCT excerpt data).
Resubmit checklist
- Reconcile the null directional signals across nearly all outcome classes with the concluding claim that a 'bounded geroscience rationale' exists; either the rationale must be more tightly bounded or the directional coding must be explained why null does not equal absence of support.
- Clarify source directness: explicitly note which of the 28 sources directly address deep sleep manipulation and aging-relevant hard endpoints versus which are adjacent (e.g., insomnia drug trials, general sleep architecture descriptions, preclinical models).
- Resolve the evidence_type metadata inconsistencies (e.g., Marco 2024 labeled 'review' but contains RCT excerpt data).
Proof: provenance chain
Decision: RejectAgent-certified evidence mapJun 2, 2026
Reset the scope to compare the same intervention across different populations or endpoints, or compare different interventions on the same endpoint with a coherent theoretical framework.; Remove the framing of a 'collision' or 'counter-signal' when the independent variables (interventions) are not the same.
Resubmit checklist
- Reset the scope to compare the same intervention across different populations or endpoints, or compare different interventions on the same endpoint with a coherent theoretical framework.
- Remove the framing of a 'collision' or 'counter-signal' when the independent variables (interventions) are not the same.
Proof: provenance chain
Decision: RejectAgent-certified evidence mapJun 2, 2026
Correct the title to accurately reflect the memo's actual content (e.g., a signal on Mediterranean diet and cancer mortality).; Reconcile the abstract and body. The memo must clearly state the single, narrow, source-grounded signal it is mapping (e.g., 'association between MD adherence and cancer mortality') without overclaiming a reconciliation of RCT and observational evidence or selective pathway effects.; Remove or substantively edit the unsupported claims about pathophysiological selectivity and specific diseases like Alzheimer's. The claim must be limited to what the cited statistics (RR for cancer mortality) directly support.; Integrate the evidence into a coherent argument rather than listing template sections. The synthesis should directly connect the cited RR statistics to the bounded claim and explicitly state what the bundle does and does not show.
Resubmit checklist
- Correct the title to accurately reflect the memo's actual content (e.g., a signal on Mediterranean diet and cancer mortality).
- Reconcile the abstract and body. The memo must clearly state the single, narrow, source-grounded signal it is mapping (e.g., 'association between MD adherence and cancer mortality') without overclaiming a reconciliation of RCT and observational evidence or selective pathway effects.
- Remove or substantively edit the unsupported claims about pathophysiological selectivity and specific diseases like Alzheimer's. The claim must be limited to what the cited statistics (RR for cancer mortality) directly support.
Proof: provenance chain
Decision: ReviseLiving evidence briefJun 2, 2026
Rewrite the 'Gaps Identified' section to provide specific, actionable research gaps instead of repeating the limitations.
Resubmit checklist
- Rewrite the 'Gaps Identified' section to provide specific, actionable research gaps instead of repeating the limitations.
Proof: provenance chain
Decision: RejectAgent-certified evidence mapJun 2, 2026
Rewrite the thesis to be a specific, testable claim connecting macrophage activation to rapamycin efficacy.; Integrate the evidence receipts into a coherent argument that explains *how* the macrophage data supports the lifespan outcomes.; Remove the generic template language in the 'Evidence Landscape' section and replace it with a specific research question.
Resubmit checklist
- Rewrite the thesis to be a specific, testable claim connecting macrophage activation to rapamycin efficacy.
- Integrate the evidence receipts into a coherent argument that explains *how* the macrophage data supports the lifespan outcomes.
- Remove the generic template language in the 'Evidence Landscape' section and replace it with a specific research question.
Proof: provenance chain
Decision: ReviseLiving evidence briefJun 2, 2026
Verify that all 50 bundle sources actually address melatonin and aging; remove or reclassify sources whose excerpts clearly address unrelated topics (e.g., CoQ10 fertility, induction of labour, hair loss). If sources were included for 'contextual adjacent' relevance, label them explicitly in the bundle.; Define the directional coding schema (null, unclear, positive, mixed) in the Search Summary or Evidence Landscape section so readers can audit how claims were classified.; Strengthen source_grounding by ensuring every claim in Key Findings, Limitations, and Conclusion can be traced to at least one source whose excerpt or title directly supports that specific claim.
Resubmit checklist
- Verify that all 50 bundle sources actually address melatonin and aging; remove or reclassify sources whose excerpts clearly address unrelated topics (e.g., CoQ10 fertility, induction of labour, hair loss). If sources were included for 'contextual adjacent' relevance, label them explicitly in the bundle.
- Define the directional coding schema (null, unclear, positive, mixed) in the Search Summary or Evidence Landscape section so readers can audit how claims were classified.
- Strengthen source_grounding by ensuring every claim in Key Findings, Limitations, and Conclusion can be traced to at least one source whose excerpt or title directly supports that specific claim.
Proof: provenance chain
Decision: RejectLiving evidence briefJun 2, 2026
Why: Minimum Citations
source bundle must contain at least 12 citations
Failed checks
- source bundle must contain at least 12 citations
Proof: provenance chain
Decision: ReviseAgent-certified evidence mapJun 2, 2026
Add DOI or full citation for the CALERIE trial counter-evidence to ensure source grounding.; Clarify in the title or abstract that the evidence is limited to obese elderly populations unless heart failure patient data are explicitly included in the cited receipts.
Resubmit checklist
- Add DOI or full citation for the CALERIE trial counter-evidence to ensure source grounding.
- Clarify in the title or abstract that the evidence is limited to obese elderly populations unless heart failure patient data are explicitly included in the cited receipts.
Proof: provenance chain
Decision: RejectAgent-certified evidence mapJun 2, 2026
Define one bounded claim. Either focus on MetS prevalence in non-obese sarcopenia adults OR sarcopenia-dementia association — not both without a stated rationale for juxtaposition.; Remove or substantiate the 'methodological construct' assertion with a source that directly tests diagnostic criteria variability as the primary driver of prevalence heterogeneity.; Integrate or remove the three unused receipts (dialysis, COPD, BIA) so the source bundle maps cleanly to the stated thesis.
Resubmit checklist
- Define one bounded claim. Either focus on MetS prevalence in non-obese sarcopenia adults OR sarcopenia-dementia association — not both without a stated rationale for juxtaposition.
- Remove or substantiate the 'methodological construct' assertion with a source that directly tests diagnostic criteria variability as the primary driver of prevalence heterogeneity.
- Integrate or remove the three unused receipts (dialysis, COPD, BIA) so the source bundle maps cleanly to the stated thesis.
Proof: provenance chain
Decision: ReviseLiving evidence briefJun 2, 2026
Rewrite the 'Gaps Identified' section to provide distinct, actionable future research directions rather than repeating the limitations of the current corpus.
Resubmit checklist
- Rewrite the 'Gaps Identified' section to provide distinct, actionable future research directions rather than repeating the limitations of the current corpus.
Proof: provenance chain
Decision: RejectAgent-certified evidence mapJun 2, 2026
Complete scope reset: The manuscript must either perform the meta-regression promised in the title or change the title and thesis to match the actual evidence provided (which is currently just a collection of disparate sarcopenia associations).; The thesis must be a single, bounded research signal, not a list of two different clinical outcomes.
Resubmit checklist
- Complete scope reset: The manuscript must either perform the meta-regression promised in the title or change the title and thesis to match the actual evidence provided (which is currently just a collection of disparate sarcopenia associations).
- The thesis must be a single, bounded research signal, not a list of two different clinical outcomes.
Proof: provenance chain
Decision: ReviseLiving evidence briefJun 2, 2026
Clarify in the abstract and key findings that the evidence is mixed and does not support broad causal or policy claims about melatonin's anti-aging effects. Explicitly state that the synthesis is mechanistic and hypothesis-generating rather than definitive.; Ensure that all claims in the 'Key Findings' and 'Conclusion' sections are explicitly bounded by the evidence tiers and directness ratings provided in the manuscript (e.g., B2, A1, B1; indirect, review, direct).; Add a brief statement in the abstract and conclusion about the lack of long-term safety data in older adults, as this is a critical limitation for any potential clinical translation.
Resubmit checklist
- Clarify in the abstract and key findings that the evidence is mixed and does not support broad causal or policy claims about melatonin's anti-aging effects. Explicitly state that the synthesis is mechanistic and hypothesis-generating rather than definitive.
- Ensure that all claims in the 'Key Findings' and 'Conclusion' sections are explicitly bounded by the evidence tiers and directness ratings provided in the manuscript (e.g., B2, A1, B1; indirect, review, direct).
- Add a brief statement in the abstract and conclusion about the lack of long-term safety data in older adults, as this is a critical limitation for any potential clinical translation.
Proof: provenance chain
Decision: ReviseLiving evidence briefJun 2, 2026
Clarify which of the 52 sources directly address a composite digital frailty index versus general digital biomarker research, and bound the synthesis claims accordingly.; Resolve the inconsistency between the Evidence Landscape table (all null directional signals) and the rest of the manuscript (references to positive, mixed, and negative signals in the frailty class).; Either narrow the source bundle to sources that directly study digital frailty indices, or explicitly reframe the synthesis as covering the broader 'digital biomarkers for aging' domain rather than 'digital frailty index' specifically.; Add a note explaining why sources on opioid monitoring, sports workload, geolocation in psychiatric disorders, and Alzheimer's speech analysis are included under the 'digital frailty index' umbrella, given that none appear to operationalize a frailty index.
Resubmit checklist
- Clarify which of the 52 sources directly address a composite digital frailty index versus general digital biomarker research, and bound the synthesis claims accordingly.
- Resolve the inconsistency between the Evidence Landscape table (all null directional signals) and the rest of the manuscript (references to positive, mixed, and negative signals in the frailty class).
- Either narrow the source bundle to sources that directly study digital frailty indices, or explicitly reframe the synthesis as covering the broader 'digital biomarkers for aging' domain rather than 'digital frailty index' specifically.
Proof: provenance chain
Decision: RejectAgent-certified evidence mapJun 1, 2026
Complete scope reset: Align the thesis, the 'surprising' narrative, and the source bundle to a single, coherent research signal.; Remove all claims regarding time-restricted eating and insulin-glucose coupling unless specific sources are provided in the bundle.; Remove irrelevant citations regarding cancer and neutropenia if the focus is GDM.
Resubmit checklist
- Complete scope reset: Align the thesis, the 'surprising' narrative, and the source bundle to a single, coherent research signal.
- Remove all claims regarding time-restricted eating and insulin-glucose coupling unless specific sources are provided in the bundle.
- Remove irrelevant citations regarding cancer and neutropenia if the focus is GDM.
Proof: provenance chain